Cilofexor

Research use only, not for human use.

Cilofexor (GS-9674, GS9674, PX-104) is a novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.

Cilofexor (GS-9674, GS9674, PX-104) is a novel specific, non-steroidal farnesoid X receptor (FXR) agonist that reduces liver fibrosis and ameliorates portal hypertension in rat NASH models.Steatohepatitis,Phase 2 Clinical(In Vivo):Cilofexor (GS-9674; 30 mg/kg; oral gavage; once daily; for 10 weeks; male Wistar rats) treatment significantly increases Fgf15 expression in the ileum and decreased Cyp7a1 in the liver in nonalcoholic steatohepatitis (NASH) rats. Liver fibrosis and hepatic collagen expression are significantly reduced. Cilofexor also significantly reduces hepatic stellate cell (HSC) activation and significantly decreases portal pressure, without affecting systemic hemodynamics.

——

Animal Model:Male Wistar rats received a choline-deficient high fat diet (CDHFD)Dosage:30 mg/kg Administration:Oral gavage; once daily; for 10 weeks Result:Significantly increased Fgf15 expression in the ileum and decreased Cyp7a1 in the liver. Liver fibrosis and hepatic collagen expression were significantly reduced.

GS-9674 | GS9674 | PX-104

Metabolic Enzyme/Protease

FXR

FXR

Other Indications

Steatohepatitis

1418274-28-8

586.85

C28H22Cl3N3O5

>98% (HPLC)

DMSO : 125 mg/mL213.00 mM; H2O : < 0.1 mg/mL

OC(C1=CC=NC(N2CC(O)(C2)C3=C(C=C(C=C3)OCC4=C(ON=C4C5=C(C=CC=C5Cl)Cl)C6CC6)Cl)=C1)=O

2-[3-[2-Chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]phenyl]-3-hydroxy-1-azetidinyl]-4-pyridinecarboxylic acid

(-20℃)

With Ice Pack

≥ 2 years